In mIDH1 mouse glioma model experiments, after TP53 and ATRX knockdown, glioma patients with IDH1-R132H exhibited increased DNA damage repair (DDR) activity and enhanced genomic stability (39). This evidence concerns the gene TP53 and central nervous system cancer.